DE60313872D1 - PYRAZOLOE1,5-ATPYRIMIDINES AS INHIBITORS CYCLINE-DEPENDENT KINASES - Google Patents

PYRAZOLOE1,5-ATPYRIMIDINES AS INHIBITORS CYCLINE-DEPENDENT KINASES

Info

Publication number: DE60313872D1
Authority: DE; Germany
Prior art keywords: pyrazoloe1; atpyrimidines; cycline; inhibitors; dependent kinases
Prior art date: 2002-09-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60313872T

Other languages

German (de)

Other versions

DE60313872T2 (en

Inventor

Timothy J Guzi

Kamil Paruch

Michael P Dwyer

Ronald J Doll

Viyyoor Moopil Girijavallabhan

Carmen S Alvarez

Tin-Yau Chan

Chad Knutson

Vincent Madison

Thierry O Fischmann

Lawrence W Dillard

Vinh D Tran

Zhen Min He

Ray Anthony James

Haengsoon Park

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Sharp and Dohme LLC

Pharmacopeia LLC

Original Assignee

Pharmacopeia Drug Discovery Inc

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-04

Filing date

2003-09-03

Publication date

2007-06-28

2003-09-03 Application filed by Pharmacopeia Drug Discovery Inc, Schering Corp filed Critical Pharmacopeia Drug Discovery Inc

2007-06-28 Publication of DE60313872D1 publication Critical patent/DE60313872D1/en

2008-01-17 Application granted granted Critical

2008-01-17 Publication of DE60313872T2 publication Critical patent/DE60313872T2/en

2023-09-04 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Psychology (AREA)

DE60313872T 2002-09-04 2003-09-03 PYRAZOLOE1,5-ATPYRIMIDINES AS INHIBITORS CYCLINE-DEPENDENT KINASES Expired - Lifetime DE60313872T2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US40802902P	2002-09-04	2002-09-04
US408029P		2002-09-04
PCT/US2003/027491 WO2004026229A2 (en)	2002-09-04	2003-09-03	Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors

Publications (2)

Publication Number	Publication Date
DE60313872D1 true DE60313872D1 (en)	2007-06-28
DE60313872T2 DE60313872T2 (en)	2008-01-17

Family

ID=32030632

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60313872T Expired - Lifetime DE60313872T2 (en)	2002-09-04	2003-09-03	PYRAZOLOE1,5-ATPYRIMIDINES AS INHIBITORS CYCLINE-DEPENDENT KINASES

Country Status (18)

Country	Link
US (2)	US7067661B2 (en)
EP (1)	EP1534712B1 (en)
JP (2)	JP4790265B2 (en)
KR (1)	KR20050033659A (en)
CN (1)	CN1701073B (en)
AR (1)	AR041133A1 (en)
AT (1)	ATE362474T1 (en)
AU (1)	AU2003298571B2 (en)
CA (1)	CA2497544C (en)
DE (1)	DE60313872T2 (en)
ES (1)	ES2283868T3 (en)
MX (1)	MXPA05002572A (en)
MY (2)	MY137843A (en)
NZ (1)	NZ539161A (en)
PE (1)	PE20041000A1 (en)
TW (1)	TWI329645B (en)
WO (1)	WO2004026229A2 (en)
ZA (1)	ZA200501846B (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4579351B2 (en)	1996-12-03	2010-11-10	スローン−ケッタリングインスティトュートフォアキャンサーリサーチ	Synthesis of epothilone and its intermediates and analogs and uses thereof
EP1388541A1 (en) *	2002-08-09	2004-02-11	Centre National De La Recherche Scientifique (Cnrs)	Pyrrolopyrazines as kinase inhibitors
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
NZ538522A (en)	2002-08-23	2008-03-28	Sloan Kettering Inst Cancer	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004026229A2 (en) *	2002-09-04	2004-04-01	Schering Corporation	Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
US7601724B2 (en) *	2002-09-04	2009-10-13	Schering Corporation	Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7205308B2 (en) *	2002-09-04	2007-04-17	Schering Corporation	Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2516824A1 (en) *	2003-02-28	2004-09-10	Teijin Pharma Limited	Pyrazolo[1,5-a]pyrimidine derivatives
EP1608652A1 (en) *	2003-03-31	2005-12-28	Vernalis (Cambridge) Limited	Pyrazolopyrimidine compounds and their use in medicine
US20070060595A1 (en) *	2003-10-10	2007-03-15	Toshio Yoshizawa	Novel fused heterocyclic compound and use thereof
WO2005112936A1 (en) *	2004-05-14	2005-12-01	The Regents Of The University Of Michigan	Compositions and methods relating to protein kinase inhibitors
ATE517901T1 (en)	2004-09-06	2011-08-15	Bayer Schering Pharma Ag	PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT)
FR2876582B1 (en) *	2004-10-15	2007-01-05	Centre Nat Rech Scient Cnrse	USE OF PYRROLO-PYRAZINE DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES ASSOCIATED WITH A DEFECT OF ADDRESSING PROTEINS IN CELLS
US7741318B2 (en)	2004-12-21	2010-06-22	Schering Corporation	Pyrazolo [1,5-A]pyrimidine adenosine A2a receptor antagonists
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2275096A3 (en)	2005-08-26	2011-07-13	Braincells, Inc.	Neurogenesis via modulation of the muscarinic receptors
DE602006016455D1 (en)	2005-09-09	2010-10-07	Schering Corp	NEW 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLOE1,5-ATPYRIDINES, PYRAZOLOE1,5-CYPYRIMIDINES, AND 2H-INDAZONE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZOESE- AÜPYRIDINEN, AND IMIDAZOÄ1,5-ATPYRAZIN COMPOUNDS AS INHIBITORS OF CYCLINE DEPENDENT KINASE
EP1940389A2 (en)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
JP2009513672A (en)	2005-10-31	2009-04-02	ブレインセルス，インコーポレイティド	GABA receptor-mediated regulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
WO2007118844A1 (en) *	2006-04-13	2007-10-25	Basf Se	Substituted pyrazolopyrimidines, process for their preparation and their use for controlling harmful fungi and compositions comprising them
EP2382975A3 (en)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenesis by modulating angiotensin
EP2027127A1 (en) *	2006-05-22	2009-02-25	Shering Corporation	Pyrazolo [1, 5-a]pyrimidines as cdk inhibitors
US8008307B2 (en)	2006-08-08	2011-08-30	Millennium Pharmaceuticals, Inc.	Heteroaryl compounds useful as inhibitors of E1 activating enzymes
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US8299241B2 (en) *	2006-12-05	2012-10-30	Arena Pharmaceuticals, Inc.	Processes for preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates thereof
JP5214799B2 (en) *	2008-04-07	2013-06-19	アイアールエム・リミテッド・ライアビリティ・カンパニー	Compounds and compositions as kinase inhibitors
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
WO2011028638A1 (en)	2009-09-04	2011-03-10	Schering Corporation	Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
PL2509602T3 (en) *	2009-12-04	2017-08-31	Senhwa Biosciences, Inc.	Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
EP2937345B1 (en)	2009-12-29	2018-03-21	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
US10953012B2 (en)	2011-04-26	2021-03-23	Bioenergenix Llc	Heterocyclic compounds for the inhibition of pask
WO2012178125A1 (en)	2011-06-22	2012-12-27	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
JP6106685B2 (en)	2011-11-17	2017-04-05	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	Inhibitors of C-JUN-N-terminal kinase (JNK)
HK1201817A1 (en)	2012-02-17	2015-09-11	Millennium Pharmaceuticals, Inc.	Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
CN102633803A (en) *	2012-05-03	2012-08-15	盛世泰科生物医药技术(苏州)有限公司	Synthetic method of 5,7-dichloro pyrazole [1,5-a] pyrimidine
WO2014063061A1 (en)	2012-10-19	2014-04-24	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
US9278973B2 (en)	2012-10-25	2016-03-08	Bioenergenix Llc	Heterocyclic compounds for the inhibition of PASK
US10392389B2 (en)	2012-10-25	2019-08-27	Bioenergenix Llc	Heterocyclic compounds for the inhibition of PASK
SMT202100425T1 (en)	2012-12-07	2021-09-14	Vertex Pharma	2-amino-n-(piperidin-1-yl-pyridin-3-yl) pyrazolo[1,5alpha]pyrimidine-3-carboxamid as inhibitor of atr kinase
BR112015022545A2 (en)	2013-03-13	2017-07-18	Constellation Pharmaceuticals Inc	pyrazole compounds and the uses thereof
EP2970289A1 (en)	2013-03-15	2016-01-20	Vertex Pharmaceuticals Inc.	Compounds useful as inhibitors of atr kinase
WO2014143240A1 (en)	2013-03-15	2014-09-18	Vertex Pharmaceuticals Incorporated	Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US8969360B2 (en)	2013-03-15	2015-03-03	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
EA032577B1 (en)	2013-07-02	2019-06-28	Милленниум Фармасьютикалз, Инк.	Heteroaryl compounds useful as inhibitors of sumo activating enzyme
CN105849099B (en)	2013-10-18	2020-01-17	达纳-法伯癌症研究所股份有限公司	Polycyclic inhibitor of cyclin-dependent kinase 7 (CDK7)
ES2676734T3 (en)	2013-10-18	2018-07-24	Syros Pharmaceuticals, Inc.	Heteroatomic compounds useful for the treatment of proliferative diseases
PT3077397T (en)	2013-12-06	2020-01-22	Vertex Pharma	2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
AU2014372638A1 (en)	2013-12-23	2016-06-16	Norgine B.V.	Compounds useful as CCR9 modulators
ES2954126T3 (en) *	2014-01-22	2023-11-20	Curovir Ab	Pyrazolo[1,5-a]pyrimidine-7-amine derivatives useful in therapy
SI3152212T1 (en)	2014-06-05	2020-06-30	Vertex Pharmaceuticals Inc.	Radiolabelled derivatives of a 2-amino-6-fluoro-n-(5-fluoro-pyridin-3-yl)- pyrazolo(1,5-a)pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
SG10201811175WA (en)	2014-06-17	2019-01-30	Vertex Pharma	Method for treating cancer using a combination of chk1 and atr inhibitors
SG11201610476VA (en)	2014-07-01	2017-01-27	Millennium Pharm Inc	Heteroaryl compounds useful as inhibitors of sumo activating enzyme
CN105294655B (en) *	2014-07-26	2019-03-15	广东东阳光药业有限公司	Compounds of CDK class small molecule inhibitors and their uses
AU2015371251B2 (en)	2014-12-23	2020-06-11	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP6861166B2 (en)	2015-03-27	2021-04-21	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	Inhibitor of cyclin-dependent kinase
CA2986441A1 (en)	2015-06-12	2016-12-15	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en)	2015-09-09	2017-03-16	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
HK1258570A1 (en)	2015-09-30	2019-11-15	Vertex Pharmaceuticals Inc.	Method for treating cancer using a combination of dna damaging agents and atr inhibitors
EA201891170A1 (en)	2015-11-18	2018-11-30	Джензим Корпорейшн	BIOMARKER OF POLYCYSTIC KIDNEY DISEASE AND OPTIONS FOR ITS APPLICATION
TWI703149B (en) *	2017-11-16	2020-09-01	美商美國禮來大藥廠	Compounds useful for inhibiting cdk7
US12187701B2 (en)	2018-06-25	2025-01-07	Dana-Farber Cancer Institute, Inc.	Taire family kinase inhibitors and uses thereof
JP7179161B2 (en)	2018-09-10	2022-11-28	イーライリリーアンドカンパニー	Pyrazolo[1,5-A]pyrimidine-3-carboxamide derivatives useful for treating psoriasis and systemic lupus erythematosus
CN112996790B (en) *	2018-10-30	2023-11-03	克洛诺斯生物公司	Compounds, compositions and methods for modulating CDK9 activity
TWI800696B (en)	2018-12-10	2023-05-01	美商美國禮來大藥廠	7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives
AU2019413694B2 (en)	2018-12-28	2025-03-20	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 and uses thereof
AR121251A1 (en)	2020-02-12	2022-05-04	Lilly Co Eli	7-(METHYLAMINO)PYRAZOLE[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS
JP7375214B2 (en)	2020-02-12	2023-11-07	イーライリリーアンドカンパニー	Substituted 7-(methylamino)pyrazolo[1,5-A]pyrimidine-3-carboxamide derivatives
CN116693538A (en) *	2022-03-04	2023-09-05	成都苑东生物制药股份有限公司	Pyrazolopyrimidine derivative, and preparation method and application thereof
CN116396298A (en) *	2023-06-06	2023-07-07	四川维亚本苑生物科技有限公司	Intermediate XII of CDK bond-1 and preparation method of CDK bond-1

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US626096A (en) *		1899-05-30		Dust-pan
JPS4116288Y1 (en)	1964-11-07	1966-07-28
JPS6157587A (en)	1984-08-29	1986-03-24	Shionogi & Co Ltd	Condensed heterocyclic derivative and antiulcerative
JP2585462B2 (en) *	1989-10-25	1997-02-26	株式会社大塚製薬工場	Pyrazolo [1,5-a] pyrimidine derivatives
JP2811020B2 (en)	1990-04-17	1998-10-15	日本特殊陶業株式会社	Joint of ceramic and steel and method of manufacturing the same
ATE174917T1 (en) *	1991-04-22	1999-01-15	Otsuka Pharma Co Ltd	PYRAZOLO(1,5-A>PYRIMIDINE DERIVATIVES AND ANTI-INFLAMMATORY AGENTS CONTAINING SAME
EP0628559B1 (en)	1993-06-10	2002-04-03	Beiersdorf-Lilly GmbH	Pyrimidine compounds and their use as pharmaceuticals
US5571813A (en)	1993-06-10	1996-11-05	Beiersdorf-Lilly Gmbh	Fused pyrimidine compounds and their use as pharmaceuticals
AU680370B2 (en)	1994-06-21	1997-07-24	Otsuka Pharmaceutical Factory, Inc.	Pyrazolo(1,5-a)pyrimidine derivative
US5919815A (en)	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
US6191131B1 (en)	1997-07-23	2001-02-20	Dupont Pharmaceuticals Company	Azolo triazines and pyrimidines
US6262096B1 (en)	1997-11-12	2001-07-17	Bristol-Myers Squibb Company	Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en)	1997-11-12	2000-03-21	Bristol-Myers Squibb Company	Aminothiazole inhibitors of cyclin dependent kinases
US6413974B1 (en)	1998-02-26	2002-07-02	Aventis Pharmaceuticals Inc.	6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6190131B1 (en) *	1999-08-31	2001-02-20	General Electric Co.	Non-integral balanced coverplate and coverplate centering slot for a turbine
FR2805160B1 (en)	2000-02-23	2002-04-05	Oreal	COMPOSITIONS FOR OXIDATION DYEING OF KERATINIC FIBERS COMPRISING N (2-HYDROXYBENZENE) -CARBRAMATE OR N- (2-HYDROXYBENZENE) -UREA AND PYRAZOLOPYRIMIDINE, AND DYEING METHODS
US7067520B2 (en)	2000-11-17	2006-06-27	Ishihara Sangyo Kaisha, Ltd.	Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
FR2817469B1 (en)	2000-12-04	2003-04-18	Oreal	COLORING COMPOSITION, PROCESS FOR OBTAINING AND USE FOR COLORING KERATINIC FIBERS
CA2432417A1 (en)	2000-12-20	2002-06-27	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.)	Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors
WO2002060492A1 (en) *	2001-01-30	2002-08-08	Cytopia Pty Ltd	Methods of inhibiting kinases
JP4500055B2 (en)	2002-04-23	2010-07-14	塩野義製薬株式会社	Pyrazolo [1,5-a] pyrimidine derivatives and NAD (P) H oxidase inhibitors containing the same
DE10223917A1 (en)	2002-05-29	2003-12-11	Bayer Cropscience Ag	New 7-amino-6-aryl-pyrazolo-(1,5-a)-pyrimidine derivatives, useful as pesticides, e.g. insecticides, acaricides, nematocides, bactericides or especially fungicides for protection of plants or materials
WO2004026229A2 (en) *	2002-09-04	2004-04-01	Schering Corporation	Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
WO2004022559A1 (en)	2002-09-04	2004-03-18	Schering Corporation	Pyrazolopyrimidines as cyclin dependent kinase inhibitors

2003
- 2003-09-03 WO PCT/US2003/027491 patent/WO2004026229A2/en not_active Ceased
- 2003-09-03 AR ARP030103188A patent/AR041133A1/en unknown
- 2003-09-03 CN CN038247011A patent/CN1701073B/en not_active Expired - Fee Related
- 2003-09-03 MX MXPA05002572A patent/MXPA05002572A/en active IP Right Grant
- 2003-09-03 KR KR1020057003527A patent/KR20050033659A/en not_active Ceased
- 2003-09-03 MY MYPI20033315A patent/MY137843A/en unknown
- 2003-09-03 JP JP2004537708A patent/JP4790265B2/en not_active Expired - Fee Related
- 2003-09-03 US US10/653,776 patent/US7067661B2/en not_active Expired - Lifetime
- 2003-09-03 ES ES03796321T patent/ES2283868T3/en not_active Expired - Lifetime
- 2003-09-03 MY MYPI20071385A patent/MY145332A/en unknown
- 2003-09-03 EP EP03796321A patent/EP1534712B1/en not_active Expired - Lifetime
- 2003-09-03 TW TW092124336A patent/TWI329645B/en active
- 2003-09-03 DE DE60313872T patent/DE60313872T2/en not_active Expired - Lifetime
- 2003-09-03 NZ NZ539161A patent/NZ539161A/en not_active IP Right Cessation
- 2003-09-03 AU AU2003298571A patent/AU2003298571B2/en not_active Ceased
- 2003-09-03 AT AT03796321T patent/ATE362474T1/en not_active IP Right Cessation
- 2003-09-03 CA CA2497544A patent/CA2497544C/en not_active Expired - Fee Related
- 2003-09-04 PE PE2003000900A patent/PE20041000A1/en not_active Application Discontinuation
2005
- 2005-03-03 ZA ZA200501846A patent/ZA200501846B/en unknown
2006
- 2006-03-31 US US11/395,676 patent/US7514442B2/en not_active Expired - Lifetime
2010
- 2010-04-06 JP JP2010088212A patent/JP2010180235A/en not_active Withdrawn

Also Published As

Publication number	Publication date
MY145332A (en)	2012-01-31
MY137843A (en)	2009-03-31
TWI329645B (en)	2010-09-01
CA2497544A1 (en)	2004-04-01
KR20050033659A (en)	2005-04-12
EP1534712B1 (en)	2007-05-16
JP4790265B2 (en)	2011-10-12
US20060178371A1 (en)	2006-08-10
ATE362474T1 (en)	2007-06-15
HK1071572A1 (en)	2005-07-22
WO2004026229A2 (en)	2004-04-01
US7514442B2 (en)	2009-04-07
US20040106624A1 (en)	2004-06-03
JP2006502184A (en)	2006-01-19
EP1534712A2 (en)	2005-06-01
CN1701073A (en)	2005-11-23
WO2004026229A3 (en)	2004-06-17
MXPA05002572A (en)	2005-09-08
US7067661B2 (en)	2006-06-27
AU2003298571B2 (en)	2006-10-19
TW200413376A (en)	2004-08-01
JP2010180235A (en)	2010-08-19
CA2497544C (en)	2010-11-02
CN1701073B (en)	2011-06-22
ZA200501846B (en)	2005-09-12
DE60313872T2 (en)	2008-01-17
AU2003298571A1 (en)	2004-04-08
ES2283868T3 (en)	2007-11-01
AR041133A1 (en)	2005-05-04
NZ539161A (en)	2006-05-26
PE20041000A1 (en)	2004-12-29

Publication	Publication Date	Title
DE60313872D1 (en)	2007-06-28	PYRAZOLOE1,5-ATPYRIMIDINES AS INHIBITORS CYCLINE-DEPENDENT KINASES
ATE452891T1 (en)	2010-01-15	PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS
DE602004012154D1 (en)	2008-04-10	PYRIDOÄ2,3-DÜPYRIMIDIN-2,4-DIAMINE AS PDE-2 INHIBITORS
ATE525377T1 (en)	2011-10-15	IMIDAZOÄ1,5-AÜPYRAZINE AS TYROSINKINASE INHIBITORS
ATE489387T1 (en)	2010-12-15	PYRIDOÄ2,1-AÜ-ISOCHINOLINE DERIVATIVES AS DPP-IV INHIBITORS
ATE505471T1 (en)	2011-04-15	AZAINDOL KINASE INHIBITORS
ATE404564T1 (en)	2008-08-15	DIAZEPINOINDOL DERIVATIVES AS KINASE INHIBITORS
DE60315516D1 (en)	2007-09-20	PYRIDAZINONE DERIVATIVES AS CDK2 INHIBITORS
ATE443054T1 (en)	2009-10-15	CYANO-PYRROLIDINES AS DPP-IV INHIBITORS
ATE437876T1 (en)	2009-08-15	HEXAHYDROPYRIDOISOCHINOLINES AS DPP-IV INHIBITORS
ATE478868T1 (en)	2010-09-15	PYRROLODIHYDROISOCHINOLINES AS PDE10 INHIBITORS
DE50304983D1 (en)	2006-10-19	HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASEINHIBITORS
DE60325032D1 (en)	2009-01-15	2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS
DE602004025258D1 (en)	2010-03-11	AMINOTRIAZOL COMPOUNDS AS PROTEIN KINASE INHIBITORS
ATE377600T1 (en)	2007-11-15	IMIDAZOPYRAZINE AS CDK INHIBITORS
ATE520671T1 (en)	2011-09-15	PYRIMIDINE-UREA DERIVATIVES AS KINASE INHIBITORS
IS7599A (en)	2004-12-15	Heterocyclic kinase inhibitors
DE602004018837D1 (en)	2009-02-12	PTIDASE-IV INHIBITORS
ATE443706T1 (en)	2009-10-15	PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS
DE60324208D1 (en)	2008-11-27	BIARYLSULFONAMIDE AS MMP INHIBITORS
DK1597007T3 (en)	2013-04-02	chuck
DE60305332D1 (en)	2006-06-22	IMIDAZOi1,2-AöPYRIDINE
DE60322544D1 (en)	2008-09-11	GLYCINAMIDE DERIVATIVES AS RAF KINASE INHIBITORS
DE60328978D1 (en)	2009-10-08	ISOCHINOLINE DERIVATIVES AS MAO-B INHIBITORS
DE502004006055D1 (en)	2008-03-13	6-arylamine-5-cyano-4-pyrimidinone as PDE9A inhibitors

Legal Events

Date	Code	Title	Description
2008-06-05	8364	No opposition during term of opposition
2009-01-29	8327	Change in the person/name/address of the patent owner	Owner name: PHARMACOPEIA,INC. (N. D. GES. D. STAATES DELAW, US Owner name: SCHERING CORP., KENILWORTH, N.J., US
2011-03-10	8327	Change in the person/name/address of the patent owner	Owner name: PHARMACOPEIA, LLC (N.D.GES.D. STAATES DELAWARE, US Owner name: SCHERING CORP., KENILWORTH, N.J., US

Date

Code

Title

Description

2008-06-05

8364

No opposition during term of opposition

2009-01-29

8327

Change in the person/name/address of the patent owner

Owner name: PHARMACOPEIA,INC. (N. D. GES. D. STAATES DELAW, US

Owner name: SCHERING CORP., KENILWORTH, N.J., US

2011-03-10